The International Probiotics Association will host its fourth IPA DC Workshop with insights from a range of experts and stakeholders, including the FDA/ CFSAN, FTC, and Health Canada. The event is held in conjunction with the US Pharmacopeia.
Yesterday four trade associations representing the dietary supplement industry sent a letter to all 535 members of the US Congress urging them to make CBD a legal dietary ingredient and to give FDA the resources to regulate the sector.
As widely predicted, the plaintiff’s bar has turned its attention to the burgeoning CBD category with a series of lawsuits alleging that products contain “significantly lower levels of CBD than advertised.”
The United Natural Products Alliance has signed a Memorandum of Understanding (MOU) with the University of Arkansas for Medical Sciences, allowing industry stakeholders access to the medical school’s analytical, technical and policy expertise.
A cannabidiol (CBD) manufacturer is calling for greater regulatory controls after independent analyses of 31 CBD-based products found varying levels of active ingredients as well as CBD-related labelling issues.
The ABC-AHP-NCNPR Botanical Adulterants Prevention Program (BAPP) has published a new Laboratory Guidance Document (LGD) on Saw Palmetto Extract to help industry stakeholders better identify adulterants.